SecBot SecBot
PRESS-RELEASE ·Filed Jun 22, 2026

BBIO

BridgeBio Pharma, Inc.
NEUTRAL
Impact 4/10
Horizondays Processed4mo ago WireGlobeNewswire
Press release · FDA
Actionable Insight • Neutral

Monitor the ICCBH 2026 presentation on June 28 for any unexpected efficacy or safety signals that could move the stock. The PROPEL 3 data has already been disclosed, this is a conference re-presentation, not a new catalyst. No trade action warranted based on this press release alone.

DirectionNeutral
Confidencehigh
Horizondays

How the stock moved after the report

NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60
Entry
$68.92
T+0 close · Jun 22, 2026 · via day close
Latest settled
−0.77%
T+60 · $68.39
Vs SPY
−2.52%
α at T+60
Horizons
All settled
through T+60
  1. T+0 · Jun 22 $68.92entry
  2. T+1 · 5mo ago −0.42%α +1.03% · $68.63
  3. T+5 · 5mo ago +1.92%α +3.98% · $70.24
  4. T+20 · 4mo ago +18.08%α +18.23% · $81.38
  5. T+60 · 2mo ago −0.77%α −2.52% · $68.39
Loading chart...

How similar events traded

How similar events traded

See how far stocks moved after events like this one.

Subscribe for Full Access

Executive Summary

BridgeBio announced additional positive data from the Phase 3 PROPEL 3 study of oral infigratinib in achondroplasia will be presented at ICCBH 2026, alongside other skeletal dysplasia and ADH1 data. This is a routine pipeline update with no new regulatory or commercial catalyst, the data was previously disclosed and the presentation is a conference update, not a new approval or trial result.

Key Facts

  • Positive data from PROPEL 3 Phase 3 study of oral infigratinib in achondroplasia to be presented in late-breaking oral at ICCBH 2026 on June 28.
  • Additional presentations include quality-of-life findings from PROPEL observational study, Phase 2/2b design for children under 3, and ADH1 CLARIFY study poster.
  • No new regulatory filing, approval, or commercial milestone announced, this is a conference data presentation update.

Financial Impact

No financial figures disclosed; pipeline update with no immediate revenue or cost impact.

Risk Factors

  • Conference presentations rarely move stock unless they contain material new data not previously disclosed, this appears to be a re-presentation of known PROPEL 3 results.
  • No timeline for regulatory submission or approval of infigratinib in achondroplasia was provided.

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
93% bullish (29 analysts)

Investment Themes

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3315189

Track record

38 reports on BBIO

Performance horizon

10 of 13 bullish or bearish reports moved the stock their way by T+20. Best: +26.76% at T+60 after the May 11, 2026 report. 14 of 15 went positive at some point.

Filters
  1. Nov 12, 20264d ago SC 13G/A Neutral 3/10 Entry $78.17 Now $78.30 +0.17% settles Dec 11
  2. Nov 9, 20267d ago Institutional Cluster Bullish 4/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  3. Nov 6, 202610d ago Press Release Neutral 2/10 Entry $77.93 Now $78.30 +0.47% settles Dec 8
  4. Oct 29, 202618d ago 8-K Bullish 6/10 No price data
  5. Oct 29, 202618d ago Press Release Bullish 6/10 Entry $74.95 Now $78.30 +4.47% settles Nov 30
  6. Oct 27, 202620d ago SC 13G Neutral 3/10 Entry $70.82 Now $78.30 +10.56% settles Nov 25
  7. Oct 22, 202625d ago Press Release Neutral 1/10 Entry $68.12 Now $78.30 +14.94% settles Nov 19
  8. Oct 13, 20264w ago 8-K Bullish 7/10 Entry $63.30 to $78.67 Now $78.30 +23.70% ▲ +24.28% +27.89% vs SPY
  9. Oct 6, 20265w ago Press Release Bullish 7/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
  10. Oct 5, 20266w ago Press Release Neutral 2/10 Entry $66.96 to $74.03 Now $78.30 +16.94% ▲ +10.56% +13.73% vs SPY
Showing 10 of 38

US Market Status

Market Closed · Opens Wed (12h)

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Jun 22, 2026